Illumina (NSDQ:ILMN) and genomic service company Novogene said today they entered into an agreement to jointly develop advanced clinical applications for reproductive health and oncology based on next-generation sequencing technology.
The collaboration will focus on providing advanced, integrated sequencing solutions to the clinical market, the company said. The 2 companies are slated to work together to create a user-friendly diagnostic system for clinical prenatal DNA and oncology testing for the Chinese market.
“As a global provider of high-quality genomic services and leading edge bioinformatics solutions, Novogene is pleased to partner with Illumina to advance the application of NGS technology in precision medicine. As the 1st company in China to purchase Illumina’s HiSeq X Ten System and the largest provider of Illumina-based sequencing capacity in China, Novogene welcomes this opportunity to improve the quality of care enjoyed by the Chinese people,” Novogene CEO Dr. Ruiqiang Li said in a press release.
Illumina will supply technology from its sequencers to be used with Novogene’s clinical application development abilities. In the collaborative effort, Novogene will provide its nucleic acid extraction, library preparation and data analysis software, the companies said.
“Illumina is very excited to collaborate with Novogene to increase access to genetic sequencing solutions in the fields of reproductive health and oncology testing in China. We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome,” Illumina Asia Pacific region GM Tim Orpin said in prepared remarks.